Clinical Trials for Non-Small Cell Lung Cancer

A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets patients with advanced or metastatic HR+/HER2-negative breast cancer, CRPC, and NSCLC who have progressed after prior therapies, and investigates PF-07248144, a KAT6A/B inhibitor, both as a monotherapy and in combination with fulvestrant, palbociclib, letrozole, or PF-07220060, a CDK4-specific inhibitor.

ClinicalTrials.gov ID: NCT04606446

Phase II Randomized Controlled Trial of Biologically Guided Stereotactic Body Radiation Therapy in Oligoprogressive Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial involves adult patients with non-small cell lung cancer, melanoma, or renal cell carcinoma with 1-5 oligoprogressive sites, treated with either standard SBRT or PET-guided SBRT that uses a biologically adaptive strategy to escalate radiation doses based on PET imaging. These patients are receiving or have received systemic therapy with checkpoint inhibitors, and the trial aims to assess the feasibility and safety of this adaptive approach.

ClinicalTrials.gov ID: NCT05830058

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Prodrug Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates the safety and efficacy of AVA6000, a fibroblast activation protein-alpha (FAP)-activated prodrug of doxorubicin, in adult patients with various locally advanced or metastatic solid tumors who have not responded to standard treatments. It involves dose-escalation and expansion phases to optimize dosing and assess therapeutic activity.

ClinicalTrials.gov ID: NCT04969835

Pilot Study of a Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adult patients with stage IV ALK-positive non-small cell lung cancer who have stable disease on ALK inhibitors, testing a peptide vaccine designed to stimulate T-cell responses to prevent resistance to ALK-targeted therapies.

ClinicalTrials.gov ID: NCT05950139

A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With ABBV-514 as a Single Agent and in Combination With Budigalimab

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial investigates the safety and potential efficacy of ABBV-514, an afucosylated monoclonal antibody targeting CCR8, as monotherapy and in combination with Budigalimab, a PD-1 inhibitor, in adults with advanced NSCLC, HNSCC, and other solid tumors resistant or intolerant to standard treatments.

ClinicalTrials.gov ID: NCT05005403

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the efficacy of single fraction stereotactic radiosurgery (SRS) versus fractionated SRS (FSRS) in patients aged 18 or older with intact brain metastases from specified solid tumors, including non-small cell lung cancer, melanoma, breast cancer, renal cell carcinoma, and gastrointestinal cancer, who have a Karnofsky performance status of 60 or above and up to eight brain metastases.

ClinicalTrials.gov ID: NCT06500455

A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial evaluates luveltamab tazevibulin, an anti-FOLR1 antibody-drug conjugate, in adult patients with previously treated advanced or metastatic non-squamous/adenocarcinoma or adenosquamous NSCLC, targeting FOLR1-expressing tumors. The study includes patients with disease progression who have undergone two to four prior systemic therapies.

ClinicalTrials.gov ID: NCT06555263

Phase 1-2 Trial of Systemically Administered VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Selected Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates VSV-IFNβ-NIS, an investigational oncolytic virus therapy that enhances immune response, in combination with the checkpoint inhibitor pembrolizumab, for patients with refractory non-small cell lung cancer (NSCLC) and neuroendocrine carcinoma (NEC) who have progressed despite prior PD-1/PD-L1 inhibitor therapy.

ClinicalTrials.gov ID: NCT03647163

A Randomized Pivotal Study Assessing the Efficacy of Targeted Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound During the Standard of Care Treatment of Brain Metastases of Non-small Cell Lung Cancer (NSCLC) Origin

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates adults with NSCLC who have untreated brain metastases, focusing on the efficacy of combining Exablate focused ultrasound with pembrolizumab, an immunotherapy targeting PD-1, versus pembrolizumab alone. Participants must have negative EGFR and ALK statuses and appropriate performance scores.

ClinicalTrials.gov ID: NCT05317858

A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial compares the efficacy and safety of acasunlimab, a bispecific antibody targeting PDL1 and 4-1BB, combined with pembrolizumab, against docetaxel in patients with PD-L1 positive metastatic non-small cell lung cancer who have previously received PD-1/PD-L1 inhibitors and platinum-based chemotherapy. Eligible participants must have measurable stage IV disease with good performance status and have been treated with one or two prior lines of therapy.

ClinicalTrials.gov ID: NCT06635824